ABERA BIOSCIENCE AB

ABERA BIOSCIENCE AB

NNGM:ABERA
6.78
SEK
-0.32
(-4.51%)
Nov 17Next Earn
ABERA BIOSCIENCE AB
NGM:ABERA
(Nordic Growth Market)

Recent

price

6.78

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Abera Bioscience AB is a Swedish biotechnology company engaged in the research, development, and commercialization of next-generation mucosal vaccines and immunotherapies based on proprietary delivery platform technologies. The company utilizes its patented BERA (Bacterial Extra-cellular Vesicle Display) platform to engineer Outer Membrane Vesicles (OMVs) derived from bacteria that display antigens on their surface, facilitating both mucosal and systemic immune protection through needle-free administration routes such as nasal sprays. Abera Bioscience operates across two primary therapeutic segments: Infectious Diseases and Immuno-Oncology. Its development pipeline and product portfolio comprise Ab-01.12, a lead universal, serotype-independent intranasal vaccine candidate targeting Streptococcus pneumoniae to prevent pneumococcal disease and mucosal colonization; preclinical mucosal vaccine candidates for viral pathogens, including seasonal and pandemic influenza; an early-stage Chlamydia vaccine program; and personalized therapeutic cancer vaccine candidates designed to deliver tumor-specific neoantigens and stimulate antitumor immune responses. The company also provides preclinical antigen design, production services, and proprietary platform licensing arrangements for academic and commercial biopharmaceutical partners. In recent developments, Abera Bioscience secured expanded grant funding and project extensions through 2026 from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance OMV-based mucosal vaccine development and manufacturing scalability; completed Good Manufacturing Practice (GMP) production and submitted a Clinical Trial Application in the Netherlands with Radboud University Medical Center to initiate Phase I clinical trials for Ab-01.12; established an independent research, development, and analytical laboratory facility in Uppsala, Sweden, to internalize antigen production and research capabilities; and entered a collaborative formulation initiative with Orexo AB to evaluate dry-powder mucosal delivery utilizing AmorphOX technology. Founded in 2012 as a spin-out from Stockholm University and Vrije Universiteit Amsterdam, Abera Bioscience AB is headquartered in Uppsala, Sweden, and operates across Sweden and the Netherlands.